Jones HE - Search Results

1

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Among authors: jones he. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780

2

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM. Nicholson RI, et al. Among authors: jones he. Rev Endocr Metab Disord. 2007 Sep;8(3):241-53. doi: 10.1007/s11154-007-9033-5. Rev Endocr Metab Disord. 2007. PMID: 17486454 Review.

3

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.

Jones HE, Gee JM, Barrow D, Tonge D, Holloway B, Nicholson RI. Jones HE, et al. Br J Cancer. 2006 Jul 17;95(2):172-80. doi: 10.1038/sj.bjc.6603237. Epub 2006 Jul 4. Br J Cancer. 2006. PMID: 16819546 Free PMC article.

4

Development of strategies for the use of anti-growth factor treatments.

Jones HE, Gee JM, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI. Jones HE, et al. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82. doi: 10.1677/erc.1.01004. Endocr Relat Cancer. 2005. PMID: 16113094 Review.

5

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.

Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Among authors: jones he. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):257-62. doi: 10.1016/j.jsbmb.2004.12.006. Epub 2005 Feb 8. J Steroid Biochem Mol Biol. 2005. PMID: 15860268 Review.

6

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Jones HE, et al. Endocr Relat Cancer. 2004 Dec;11(4):793-814. doi: 10.1677/erc.1.00799. Endocr Relat Cancer. 2004. PMID: 15613453

7

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: jones he. Endocr Relat Cancer. 2001 Sep;8(3):175-82. doi: 10.1677/erc.0.0080175. Endocr Relat Cancer. 2001. PMID: 11566608 Review.

8

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Nicholson RI, et al. Among authors: jones he. Ann N Y Acad Sci. 2002 Jun;963:104-15. doi: 10.1111/j.1749-6632.2002.tb04101.x. Ann N Y Acad Sci. 2002. PMID: 12095935

9

Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.

Jones HE, Barrow D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI. Jones HE, et al. Prostate. 2001 Sep 15;49(1):38-47. doi: 10.1002/pros.1116. Prostate. 2001. PMID: 11550209

10

New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.

Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI. Jones HE, et al. Int J Cancer. 1997 Jun 11;71(6):1010-8. doi: 10.1002/(sici)1097-0215(19970611)71:6<1010::aid-ijc17>3.0.co;2-h. Int J Cancer. 1997. PMID: 9185705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results